FUNDING-Integrative Research on Polysubstance Abuse and Addiction (R21/R33 Clinical Trial Optional); February 16, 2018

 

 

Agency

 

National Institute on Drug Abuse

National Institute on Alcohol Abuse and Alcoholism

National Cancer Institute

 

Description

This Funding Opportunity Announcement (FOA) is supported by Collaborative Research on Addiction (CRAN) at the National Institutes of Health (NIH), a trans-NIH partnership composed of the National Institute on Alcohol Abuse and Alcoholism (NIAAA), the National Institute on Drug Abuse (NIDA), and the National Cancer Institute (NCI). The intent of this FOA is two-fold: (1) characterize how the neurobiological alterations, associated behaviors, and public health consequences arising from polysubstance use differ from, or are similar to, those observed in single drug use; (2) promote integrative polysubstance research along a translational pipeline, consisting of basic science research in animals, human-based laboratory investigations, and epidemiological studies. These dual objectives will be accomplished with a Phased Innovation (R21/R33) mechanism, where polysubstance research can occur in any of these translational stages during the R21 phase and these findings will be rapidly back- or forward-integrated into another stage during the R33 phase, allowing for bi-directional research exchange.

 

Activity Code:

 

R21/R33 Phased Innovation Award

 

Announcement Number:

 

PAR-18-084

 

Closing Date:

 

February 16, 2018

 

Link to Full Announcement

 

http://grants.nih.gov/grants/guide/pa-files/PAR-18-084.html